SPL & GUDID/UDI Submissions: Drug and Device Labeling to the FDA

Definition

Structured Product Labeling (SPL) is the FDA’s XML-based submission format for drug establishment registration, drug listing, and labeling data, typically transmitted through the Electronic Submissions Gateway (ESG). GUDID/UDI submission is the separate device-side process for sending key device identification data to FDA’s Global Unique Device Identification Database (GUDID), rather than drug listing or full drug labeling content. FDA drug registration and listing instructions

Buyers often group these together because both involve structured electronic submissions to the FDA, but they solve different regulatory jobs. SPL is the heavier submission framework used in drug registration and listing; GUDID is narrower and centered on device identifier records. FDA GUDID guidance

Why the distinction matters

The practical mistake to avoid is treating device UDI work as if it were the device equivalent of drug SPL. It is not. For drugs, SPL carries establishment, listing, NDC, and labeling information in a structured XML format that FDA uses in its electronic drug registration and listing system. For devices, GUDID stores key device identification information tied to the Device Identifier (DI), while device establishment registration and device listing are handled separately. FDA eDRLS

That difference affects staffing, tooling, and risk. Drug teams usually need stronger XML/SPL discipline because the submission package is doing more regulatory work. Device teams more often need to keep establishment registration, device listing, and UDI/GUDID data aligned so the same product is described consistently across systems. FDA GUDID guidance

How each submission works

FDA drug registration instructions and FDA GUDID guidance

For drugs, FDA describes three core submissions in the registration-and-listing workflow: establishment registration, labeler code, and drug product listing. The product listing portion includes the current labeling and package images, which is why SPL work is often more document-intensive than buyers first expect. FDA drug registration and listing instructions

For devices, GUDID can be updated through the FDA web interface or through HL7 SPL XML submitted via ESG. That sometimes creates naming confusion: devices can use an SPL-based technical pathway for GUDID transmission, but that does not make device UDI submission the same regulatory object as drug SPL listing. FDA GUDID guidance

Cadence and update rules

Drug establishment registration renews annually between October 1 and December 31. Drug listing information must be updated twice each year, in June and December, if information has changed; FDA also allows an annual no-change certification during the October-to-December renewal window for listings that did not otherwise require updates that year. FDA drug registration and listing instructions

For devices, annual establishment registration and device listing maintenance are separate from GUDID. FDA Entry Point’s device materials describe annual device listing review and note that UDI/GUDID submission is filed separately from FURLS device listing, which is the operational distinction many importers and early-stage medtech teams need made explicit. FDA Entry Point medical device listing page

Real usage examples

Example 1: OTC drug manufacturer adding a new SKU

A foreign OTC manufacturer launches a new package size. The team may need a new or updated drug listing SPL submission with the relevant NDC and current labeling, plus any related annual registration maintenance if the renewal window is open. This is drug-side SPL work, not GUDID. FDA drug registration and listing instructions

Example 2: Device company assigning a UDI

A Class II device maker has already handled establishment registration and device listing, but now needs the device’s identifier data reflected in GUDID. That submission goes to the device database and centers on the DI record; production identifiers are not submitted to or stored in GUDID. FDA GUDID guidance

Example 3: Regulatory team outsourcing the XML work

A pharma or device company may keep regulatory ownership in-house but outsource the submission mechanics. FDA’s GUDID guidance explicitly contemplates third-party submitters, while making clear that the labeler remains responsible for the information submitted. That is a useful model for teams that need execution help without giving up accountability. FDA GUDID guidance

Common misconceptions

SPL is not a generic term for all FDA product submissions

In buyer conversations, “SPL” is often used loosely to mean any structured FDA upload. More precisely, SPL is the standardized XML format FDA uses for drug establishment registration and drug listing, and it is also used as a technical submission option in some other contexts such as GUDID. The workflow, however, still depends on the product category and database involved. FDA SPL resources

GUDID does not replace device listing

Device listing identifies the products marketed in the U.S.; GUDID submission provides the UDI-related device identifier data in a separate system. Treating one as a substitute for the other is a common operational error. FDA Entry Point medical device listing page

NDC and UDI solve different identification problems

NDC is FDA’s universal product identifier for drugs in the listing context, while UDI is the device identification framework. Crossing those concepts usually signals that a team is mixing drug and device workflows. FDA drug registration instructions

Where FDA Entry Point fits

FDA Entry Point offers SPL/DRLM submission support for drugs and GUDID/UDI submission support for devices as part of its broader FDA compliance services. On the device side, the company positions this alongside establishment registration and device listing support, which is the more useful framing for buyers than treating UDI as a standalone checkbox. FDA Entry Point medical device listing page

For foreign manufacturers, that matters because the submission itself is rarely the whole job. The harder part is usually keeping registrations, listings, identifiers, and labeling changes synchronized so nothing drifts out of date across FDA systems. FDA Entry Point homepage

Related terms

• SPL: Structured Product Labeling, the FDA-accepted XML standard used for drug registration, listing, and labeling submissions. FDA SPL resources

• XML: Extensible Markup Language, the machine-readable format used to structure SPL submissions.

• ESG: Electronic Submissions Gateway, the FDA transmission channel used for electronic submissions including drug SPL and some GUDID HL7 SPL submissions. FDA ESG submission instructions

• DRLM: Drug Registration and Listing Module, the FDA workflow context for electronic drug establishment registration and listing.

• NDC: National Drug Code, the drug product identifier submitted as part of FDA drug listing. FDA NDC listing instructions

• GUDID: Global Unique Device Identification Database, the FDA repository for key device identification information. FDA GUDID guidance

• UDI: Unique Device Identifier, the device identification framework that supports traceability and database submission.

• Establishment registration: The facility-level registration step required in both drug and device workflows, but maintained under different regulatory systems and cadences.

• Drug listing: The product-level drug submission that ties NDC, labeling, and manufacturing information to FDA’s listing system. FDA eDRLS

References

• FDA — Electronic Drug Registration and Listing Instructions

• FDA — Electronic Drug Registration and Listing System (eDRLS)

• FDA — Structured Product Labeling Resources

• FDA — Global Unique Device Identification Database (GUDID) Guidance

• FDA Entry Point — Medical Device Listing, IVD & UDI Support

• FDA Entry Point — Homepage